JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES药学与制药科学杂志
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES(英文缩写 J PHARM PHARM SCI),ISSN 1482-1826,eISSN 1482-1826,中文译名:药学与制药科学杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES 最新收录文献
-
1. Effects of music elements on mycophenolate glucuronidation in rat liver microsomes.
PMID:期刊:日期:2026-09-17Mycophenolic acid (MPA), a first-line immunosuppressant for preventing transplant organ rejection, exhibits substantial inter- and intra-individual pharmacokinetic variability. We hypothesized that music elements (tempo, rhythm, and harmony) can affect the formation of MPA glucuronide (the major, inactive metabolite, MPAG) and MPA acyl glucuronide (the minor, toxic metabolite, AcMPAG) in Sprague Dawley (SD) rats. SD rats (8-10 weeks; 200-300 g; N = 8 per group [equal sex]) were exposed for 24 h in a sound-monitored room with music combinations (fast or slow tempo with regular or irregular rhythm) versus controls. Liver microsomes were analysed for MPAG and AcMPAG formation under initial velocity conditions. As FT IR (fast tempo with irregular rhythm) significantly reduced AcMPAG formation, we further tested harmony (tonal vs. atonal [AH]) within FT IR using three independent composers and two published pieces. MPA glucuronides were quantified by liquid chromatography-tandem mass spectrometry. Enzyme kinetics in FT IR AH versus controls were determined across MPA concentrations (0-320 μg/mL). mRNA and protein expression of the AcMPAG-forming enzyme (UDP-glucuronosyltransferase UGT2B1) and other expressed UGTs were analysed. MPAG formation was unaffected by any music combination, whereas niflumic acid (100 μM, positive control) reduced it by ∼67%. AcMPAG formation was significantly reduced by FT IR (42.5 ± 14.4%; mean ± SEM; p < 0.05) and further reduced with added AH (74.4 ± 10.8%; p < 0.005). For MPAG, and were comparable to controls, with a modestly higher . For AcMPAG, and decreased by 89.7 ± 46.4% and 91.5 ± 29.7%, respectively (p < 0.05, n = 7 [3 males, 4 females]), with no change in . No sex differences in kinetic parameters were observed for either analyte. Inter-composer differences in MPA glucuronidation could be explained by the legato (continuous)-to-staccato (intermittent) articulation ratio. Hepatic mRNA and protein expression were unchanged after FT IR AH exposure, as were hepatic and mRNA. Our novel findings indicate that specific music elements (FT IR AH) reduced generation of the minor, toxic AcMPAG without affecting formation of the major, inactive MPAG. This is potentially therapeutically beneficial, as the adverse effects of MPA might be selectively attenuated without altering its clearance or therapeutic outcomes.
-
2. Age-related risk factors for leftover drugs: a lifespan analysis in community pharmacies.
PMID:期刊:日期:2026-09-04Medication adherence is a critical global challenge because suboptimal adherence reduces therapeutic efficacy and increases healthcare costs. While leftover drugs are vital indicators of potential adherence-related challenges, age-specific factors contributing to their occurrence, particularly across the lifespan, remain insufficiently understood. This study was aimed at clarifying age-stratified factors associated with leftover drugs using large-scale objective data from protocol-based pharmacotherapy management (PBPM) in community pharmacies. This was a single-center, retrospective, observational cohort study of 36,340 outpatients. Objective reporting of data based on the PBPM in community pharmacies between 2016 and 2021 was analyzed. Multivariate logistic regression and predicted probability models were used to evaluate the interactions between age (decade-stratified) and four primary clinical factors: drug count, prescription duration, prescribing department count, and sex. The overall proportion of leftover drugs was 9.6% ( = 3,472). In the overall population comparison, no significant differences were observed in terms of sex, but the patients in the leftover group were significantly older and had higher medication counts, longer prescription durations, and more prescribing departments. Multivariate analysis revealed significant interactions between age and each of the three primary prescription-related factors. The impact of clinical characteristics on the proportion of leftover drugs varied distinctly across life stages. Specifically, long-term prescription was the most potent risk factor for younger adults (20s-40s), whereas polypharmacy and multidepartment visits were the primary factors associated with leftover drugs for older patients. Predicted probability models indicated that having fewer than five prescribed medications was consistently associated with a lower likelihood of leftover drugs across all age groups. This study highlights the influence of clinical characteristics on leftover drug shifting substantially with age. Consequently, effective management requires age-specific interventions centered on minimizing drug counts, with an emphasis on optimizing prescription duration in younger adults and promoting medication simplification and inter-institutional coordination in older adults.
-
3. Integration of microphysiological systems with computational and digital twin modeling for pharmaceutical development: a systematic review.
PMID:期刊:日期:2026-09-04The pharmaceutical industry faces a productivity crisis, with only ∼10% of candidates reaching approval and development costs exceeding $1-2 billion per drug. Traditional preclinical models, particularly animal studies, show limited predictive validity for human outcomes. Microphysiological systems (MPS), including organ-on-chip devices, integrated with digital twin computational modeling, offer a promising route to improve translational prediction, yet no systematic assessment exists. To identify, evaluate, and synthesize the published literature on integrating MPS with digital twin computational modeling for pharmaceutical development. Following PRISMA 2020 guidelines (PROSPERO: CRD420251274941), PubMed and Europe PMC were searched from January 2010 to December 2025. Studies were included if they integrated MPS platforms with computational models (PBPK, QSP, IVIVE, PK/PD, or machine learning). Two-stage automated screening with independent verification by two researchers was applied. Data extraction captured organ systems, model types, platforms, validation approaches, pharmacokinetic parameters, software, and economic considerations. Of 2,044 records, 123 studies met inclusion criteria. Publication activity grew exponentially (CAGR ∼35%), with 38.2% published in 2024-2025. Liver was the most represented organ (30.9%), followed by vasculature (19.5%), gut (18.7%), and immune components (17.1%). PBPK was the predominant computational approach (18.7%), followed by PK (12.2%), IVIVE (12.2%), and machine learning (9.8%). Commercially, Emulate led (55.8%), then Mimetas (23.3%) and CN Bio (19.2%); custom/academic platforms comprised 74.2%. Validation was robust, with 95.8% discussing clinical data comparisons and 77.5% reporting average fold error. Only liver-PBPK and liver-PK qualified as established combinations (>5 studies), with many organ-model pairings unexplored. Multi-organ systems showed accelerating adoption after 2021. Economic themes were discussed qualitatively, but formal health economic analyses were absent. MPS-digital twin integration has matured from an emerging concept into a research paradigm with demonstrated translational value. Validation practices are strong and aligned with regulatory expectations, supported by the FDA Modernization Act 2.0 and the ISTAND program's acceptance of Liver-Chip technology. Liver-focused applications are the most mature and should serve as a template for expansion. Priority gaps include kidney, lung, and brain MPS-computational integration, multi-organ systems, and rigorous health economic analyses. Continued standardization and regulatory engagement will be essential to realize this approach's potential.
-
4. Fenofibrate in ophthalmology: therapeutic efficacy and mechanisms.
PMID:期刊:日期:2026-09-03Ophthalmic diseases are a growing global cause of visual impairment, driven by population aging and the rising prevalence of diabetes mellitus. Fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist widely used for dyslipidemia, has emerged as a candidate for therapeutic repurposing in ophthalmology. This narrative review synthesizes current preclinical and clinical evidence on fenofibrate across anterior and posterior segment diseases, including diabetic corneal neuropathy, diabetic keratopathy, dry eye disease, corneal burns, Fuchs endothelial corneal dystrophy, diabetic retinopathy, diabetic macular edema, neovascular age-related macular degeneration, and central retinal artery occlusion. Across ocular disease models, fenofibrate demonstrates neuroprotective, vascular stabilizing, and tissue-remodeling effects. These actions appear to involve modulation of shared pathogenic pathways, including PPARα-dependentregulation of inflammatory signaling, mitochondrial and lipid metabolism, and preservation of epithelial, endothelial, neuronal, and vascular integrity. Clinical evidence is strongest for diabetic retinopathy, where randomized trials support a potential adjunctive role in slowing progression and reducing interventions in patients with early-to-moderate disease. Preliminary clinical evidence for diabetic corneal neuropathy is promising but limited, whereas data for dry eye disease, corneal burns, Fuchs endothelial corneal dystrophy, neovascular age-related macular degeneration, and retinal ischemic injury remains preclinical. Emerging experimental ocular delivery strategies may improve local bioavailability while reducing systemic exposure. Overall, fenofibrate represents a biologically plausible adjunctive ophthalmic therapy, but further randomized trials, mechanistic studies, pharmacokinetic evaluation, and long-term safety assessments are required to define its therapeutic role beyond diabetic retinopathy.
-
5. {"_":"Innovative hyaluronic acid-decorated quatsomes for enhanced renal targeting: design, optimization and biochemical and nephroprotective assessments.","i":["in-vivo"]}
PMID:期刊:日期:2026-07-24The kidney plays a critical role in metabolite excretion, fluid regulation, and homeostasis, yet remains highly vulnerable to structural and functional disorders. Kidney diseases represent a major global health burden, often progressing to chronic complications due to the limited efficacy and poor selectivity of conventional therapies, which are frequently associated with systemic toxicity. Accordingly, the development of targeted drug delivery systems is essential to improve therapeutic outcomes. In this study, advanced quatsomes were developed as a kidney-targeted nanosystem to enhance the delivery of curcumin, a natural polyphenolic compound with potent antioxidant and nephroprotective properties. The system was composed of di-dodecyl-dimethyl-ammonium bromide (DDAB), cholesterol, limonene, hyaluronic acid (HA) and surfactants, and was fabricated using the ethanol injection method. A 2 factorial design was employed to optimize formulation variables, including DDAB:cholesterol ratio, limonene:drug ratio, and surfactant concentration. The optimized formulation (desirability = 0.950) exhibited high entrapment efficiency (87.80%), nanosized vesicles (120.55 nm), and a positive surface charge (+38.30 mV). Transmission electron microscopy confirmed spherical morphology, while release studies demonstrated a biphasic profile. The formulation also showed good physicochemical stability and enhanced antioxidant activity. Mechanistically, passive targeting via nanoscale size and cationic charge facilitated interaction with the glomerular filtration barrier and mesangial uptake, while limonene improved vesicle deformability. HA functionalization further enabled CD44-mediated active targeting. , the optimized system significantly reduced serum creatinine and blood urea nitrogen levels in a cisplatin-induced nephrotoxicity model, with histological evidence of renal protection. Overall, the developed quatsomes demonstrate promising potential as an efficient renal-targeted nanocarrier.
-
6. Drug-related problems and their predictors in pediatric community-acquired infections: the role of pharmacist-led interventions in Pakistan.
PMID:期刊:日期:2026-07-16Drug-Related Problems (DRPs) are a leading cause of preventable harm to hospitalized children, yet the data from low- and middle-income countries (LMICs) are limited. This study aimed to determine the prevalence, severity and determinants of DRPs in children with community-acquired infections (CAIs) using standard classification, and to quantify clinical and economic impact of pharmacist-led interventions. A prospective interventional study conducted (June 2024-March 2025), in pediatric ward of tertiary care public hospital, Karachi, Pakistan. Children aged 2months-14 years with CAIs were enrolled. A trained pharmacist reviewed medication orders daily, identifying DRPs (classified by PCNE V9.1 and severity by NCC MERP criteria). Interventions were proposed to physicians and acceptance rates recorded. Direct cost savings were calculated and DRP predictors were identified using logistic regression. A total of 3,842 medication orders were reviewed for 400 patients, identifying 2,010 DRPs (5.03 DRPs/patient). Primary causes were dose-selection (C3-58.13%), drug-form (C2-15.01%), and drug-selection (C1-13.08%). Severity assessment classified 9.0% of errors as having potential to cause serious harm. Pharmacist interventions had 98.7% acceptance and 81.1% DRPs were resolved. Number of medications (AOR 1.32), fever (AOR 2.84) and length of stay >7days (AOR 1.76) were identified as predictors of DRPs; past immunization was protective (AOR 0.51). Direct cost saving was PKR 363,184 (USD1,290) over 10 months (23:1 cost ratio). Cost per DRP prevented was PKR 241 (USD 0.86), with 142% return on investment. DRPs affected 52.3 per 100 medication orders in hospitalized children with CAIs, with dose selection DRPs predominant and 9% having serious harm potential. Pharmacist-led interventions demonstrated a 98.7% acceptance rate and 81.1% resolution of DRPs, and were associated with substantial cost savings, providing evidence for integrating clinical pharmacy services in LMICs.
-
7. The cross-talk between GSK-3β, RKIP, and PTEN as potential targets for therapeutic implications in cancer: a comprehensive insight.
PMID:期刊:日期:2026-06-25The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially identified and studied in the regulation of glycogen synthesis. In some cases, suppression of GSK-3 activity by phosphorylation by Akt and other kinases has been associated with cancer progression. In these cases, GSK-3 has tumor suppressor functions. In other cases, GSK-3 has been associated with tumor progression by stabilizing components of the beta-catenin complex. In these situations, GSK-3 has oncogenic properties. The Raf kinase inhibitor protein (RKIP) has been reported to be under expressed in many cancers and plays a role in the regulation of tumor cells' survival, proliferation, invasion, and metastasis, hence, a tumor suppressor. RKIP also regulates tumor cell resistance to cytotoxic drugs/cells. Likewise, the tumor suppressor, phosphatase and tensin homolog (PTEN), which inhibits the phosphatidylinositol 3 kinase (PI3K)/protein kinase B (Akt) pathway, is either mutated, under expressed, or deleted in many cancers and shares with RKIP its anti-tumor properties and its regulation in resistance. Several pathways are regulated by RKIP, GSK-3, PTEN, and the transcriptional and post-transcriptional regulations of RKIP, GSK-3, and PTEN are significantly altered in cancers. In addition, RKIP, GSK-3 and PTEN play a key role in the regulation of tumor cells response to chemotherapy and immunotherapy. In this review, we will focus on the roles that GSK-3, PTEN, and RKIP play in various human cancers. We will also discuss how this pivotal kinase interacts with multiple signaling pathways such as: PI3K/PTEN/Akt/mechanistic target of rapamycin complex 1 (mTORC1), nuclear Factor kappa-B (NF-κB)/Snail family transcriptional repressor 1 (Snail)/Yin Yang 1 (YY1) loop, and rat sarcoma virus oncogene (Ras)/rapidly accelerated fibrosarcoma (Raf)/mitogen-activated protein kinase (MEK)/extracellular signal-regulated kinase (ERK).
-
8. Quality by design in public healthcare: a rapid development framework for future pandemics.
PMID:期刊:日期:2026-06-25The growing number of pandemics and emergencies traversing the world in recent decades has illustrated the vulnerability of the conventional pharmaceutical development process and the necessity of an efficient, robust, and patient-driven pandemic-ready development model. QbD is a scientifically proven proactive approach that has been comprehensively examined recently for its potential to effectively optimize formulations in an accelerated time frame. Risk factor assessment and constant surveillance serve to maintain the product quality & standards before the final stage of large-scale production and offer regulatory pliability. The extension of this method, AQbD, paired side by side also assists in accelerated assessment and quality assurance which is a critical component in any global circumstance. In recent years studies have been done by applying this novel approach, but very little has been reported on the establishment of this approach as a Pandemic-Ready Development Framework. This mini review addresses the regulatory basis alongside the key principles of QbD, which aligns its working approach as optimally compatible with any pandemic situation. Furthermore, it emphasizes the widespread implementation of this approach as AQbD, which stands for swift testing coupled with quality assurance standards. It also focuses on the limitations and critical areas where QbD can be applied to cope with existing demands in near future. Further, it applies this approach in several formulation developments pertinent to pandemic or endemic conditions and discusses the challenges of implementation and future directions. Overall, this discussion stresses the potential of this approach as a very promising framework for future pandemics.
-
9. Old drugs, new weapons: current trends in repurposing therapies against antimicrobial resistance.
PMID:期刊:日期:2026-06-05Antimicrobial resistance (AMR) is a globally accelerating issue threatening the efficacy of existing treatments. Repurposing approved drugs for the development of new antimicrobial agents reduces the development cost and risk. The clinical potential of repurposed medications for AMR is essential to implement coordinated strategies that encompass scientific validation and supportive regulatory frameworks. Repurposing serves as a strong method to prolong the effectiveness of current antimicrobial classes and to fill significant voids in the global AMR pipeline. The present review summarizes current trends in repurposing strategies against AMR, utilization of non-antibiotic drugs with antibacterial activity, agents that potentiate conventional antibiotics through membrane disruption or efflux pump inhibition, and host-directed therapies that modulate immune responses and combination therapies. We also highlight advances in systems pharmacology, screening, and phenotypic assays that enable rational identification of repurposing candidates. Although significant regulatory and economic barriers persist, including weak intellectual property protection, limited commercial incentives, and market constraints, swift attempts are being made to address the issues.
-
10. Dissolution-permeation approach for biopharmaceutical evaluation: a feasibility study using naproxen.
10. 用于生物制药评价的溶出-渗透方法：使用萘普生的可行性研究PMID:期刊:日期:2026-05-11[中文摘要] 仅凭溶出度和/或释放曲线不足以预测难溶性药物的吸收。因此，渗透性试验成为生物药剂学评价的关键组成部分。目前，现有的溶出-渗透系统均未包含药典规定的溶出度测定，也未提供大体积接受室，或与膜材料不兼容。针对现有溶出-渗透测试系统的局限性，我们提出将Ussing（渗透性）室与溶出仪集成。所组装的溶出-渗透系统评估了十二烷中5%和10%大豆L-α-磷脂酰胆碱（LiDo）以及可渗透膜材料对萘普生（一种BCS II类药物）表观渗透系数的影响。萘普生从片剂中的释放约在30分钟内达到近100%。在5% LiDo条件下，萘普生通过0.45 µm PVDF膜的表观渗透系数（P）为0.91 ± 0.35 × 10 cm/s，10% LiDo条件下为0.75 ± 0.23 × 10 cm/s。0.20 μm PC膜在5% LiDo条件下的P为1.99 ± 0.57 × 10 cm/s。所提出的带Ussing室的药典溶出-渗透系统能够同时测定萘普生的溶出度和渗透性。所获得的所有P值均比文献报道值低约100倍。该结果可能受到漏槽条件和可渗透膜组成差异的影响。与PVDF膜相比，使用PC膜可获得更高的渗透性。经充分改进后，该方法可推广用于膜溶出-渗透性测试。
[英文摘要] Dissolution and/or release profile alone are insufficient to predict the absorption of poorly soluble drugs. Thus, permeation test becomes a critical component for biopharmaceutical assessment. Currently, none of the dissolution-permeation systems include the compendial dissolution, or provide large acceptor volumes, or are compatible with membranes. Addressing the limitations of the existing dissolution-permeation testing systems, we propose the integration of the Ussing (permeability) chamber to the dissolution apparatus. The assembled dissolution-permeation system evaluated the effect of 5% and 10% soy L-α-phosphatidylcholine in dodecane (LiDo) and permeable membrane material on apparent permeability coefficients of naproxen, a BCS II class drug. Naproxen release from the tablets reached approximately 100% within 30 min. Naproxen P across a 0.45 µm PVDF membrane was 0.91 ± 0.35 × 10 cm/s for 5% LiDo, and 0.75 ± 0.23 × 10 cm/s for 10% LiDo. The 0.20 μm PC membrane with 5% LiDo showed a P of 1.99 ± 0.57 × 10 cm/s. The proposed compendial dissolution-permeation system with an Ussing chamber allowed for the simultaneous determination of dissolution and permeability of naproxen. All P values obtained were approximately 100-fold lower than those reported in the literature. The results may have been influenced by the differences in sink conditions and permeable membrane composition. The use of a PC membrane resulted in higher permeability, compared to the PVDF membrane. Adequately improved, this methodology could be transferred for the membrane dissolution-permeability testing.